Ruixue Sun, Na Li, Dongdong Han, Jing Yang, Xuezhong Yu, Huadong Zhu. Clinical Features and Prognosis of Thrombotic Thrombocytopenic Purpura[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 154-159. doi: 10.3969/j.issn.1674-9081.2018.02.010
Citation: Ruixue Sun, Na Li, Dongdong Han, Jing Yang, Xuezhong Yu, Huadong Zhu. Clinical Features and Prognosis of Thrombotic Thrombocytopenic Purpura[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 154-159. doi: 10.3969/j.issn.1674-9081.2018.02.010

Clinical Features and Prognosis of Thrombotic Thrombocytopenic Purpura

doi: 10.3969/j.issn.1674-9081.2018.02.010
More Information
  • Corresponding author: ZHU Hua-dong   Tel: 010-69159131 ,Email:zhuhuadong1970@126.com
  • Received Date: 2017-12-18
  • Publish Date: 2018-03-30
  •   Objective   The aim of this study was to explore the clinical characteristics and prognosis of thrombotic thrombocytopenic purpura (TTP).  Methods   Clinical manifestations, laboratory examinations, diagnosis, therapeutic methods, and prognosis of 60 TTP patients diagnosed between 2012 and 2017 in Peking Union Medical College Hospital were retrospectively analyzed. Risk factors of prognosis were analyzed by single factor and multivariate Logistic regression analysis, and the influence of therapeutic strategieson prognosis was analyzed by Kruskal-Wallis test and Mann-Whitney U test.   Results   Among 60 TTP patients, 17 were males (28.3%, 17/60) and 43 were females (71.7%, 43/60), aged (41±15) years old. Twenty-eight patients (46.7%, 28/60) had Triad Syndrome including fever, microangiopathic hemolytic anemia, and thrombocytopenia; 23 patients (38.3%, 23/60) had Quinary Syndrome including fever, microangiopathic hemolytic anemia, thrombocy-topenia, renal insufficiency, and neurological symptoms; and the other 9 patients (15.0%, 9/60) have neither the typical Triad Syndrome nor the Quinary Syndrome. Twenty-eight patients received the measurement for ADAMTS13 activity and 23 (82.1%, 23/28) was < 10% among whom; ADAMTS13 inhibitor was tested in 20 patients with 18 (90.0%, 18/20) of them being positive; 20 patients received these both tests and the double positive rate was 90% (18/20). Different treatments, which included plasma exchange, glucocorticoids, rituximab, immunosuppresors, and intravenous immunoglobulin, were given based on patients' financial situation and blood fountain; 42 patients (70.0%, 42/60) were relieved and 18 patients died (30.0%, 18/60). The combined immunosuppressive therapy on the basis of plasma exchange and glucocorticoids improved the remission rate from 57.1% to 85.2% (P=0.032). No risk factor was found between the dead group and the remission group.   Conclusions   Most of TTP patients manifest the Triad Syndrome or the Quinary Syndrome. The decline of ADAMTS13 activity and its inhibitor have high positive rates in TTP. Immunosuppressive therapy can improve the prognosis.
  • loading
  • [1] Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features [J]. Pediatr Blood Cancer, 2013, 60: 1676-1682. doi:  10.1002/pbc.24612
    [2] Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 [J]. Blood Adv, 2017, 1: 590-600. doi:  10.1182/bloodadvances.2017005124
    [3] Nokes T, George JN, Vesely SK, et al. Pulmonary involve-ment in patients with thrombotic thrombocytopenic purpura [J]. Eur J Haematol, 2014, 92: 156-163. doi:  10.1111/ejh.12222
    [4] Hawkins BM, Abu-Fadel M, Vesely SK, et al. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review [J]. Transfusion, 2008, 48: 382-392. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1097/POC.0000000000000158
    [5] Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura [J]. Blood, 2012, 119: 5888-5897. doi:  10.1182/blood-2012-02-408914
    [6] George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010 [J]. Blood, 2010, 116: 5551-5562.
    [7] Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura [J]. Blood, 2010, 115: 1500-1511. doi:  10.1182/blood-2009-09-243790
    [8] Sculy M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies [J]. Br J Haematol, 2012, 158: 323-335. doi:  10.1111/j.1365-2141.2012.09167.x
    [9] Hie M, Gay J, Galicier L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura [J]. Blood, 2014, 124: 204-210. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7cefe4a1bb45280cb221a09650cf74ef
    [10] George JN. Congenital thrombotic thrombocytopenic purpura: lessons for recognition and management of rare syndromes [J]. Pediatr Blood Cancer, 2008, 50: 947-948. doi:  10.1002/pbc.21481
    [11] Mise K, Ubara Y, Matsumoto M, et al. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report [J]. BMC Nephrol, 2013, 14: 156-160. doi:  10.1186/1471-2369-14-156
    [12] Alford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathichaemolytic anemias [J]. Br J Haematol, 2003, 120: 556-573. doi:  10.1046/j.1365-2141.2003.04049.x
    [13] Han B, Page EE, Stewart LM, et al. Depression and cogni-tive impairment following recovery from thrombotic thrombocytopenic purpura [J]. Am J Hematol, 2015, 90: 709-714. doi:  10.1002/ajh.24060
    [14] Griffin D, Al-Nouri ZL, Muthurajah D, et al. First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? [J]. Transfusion, 2013, 53: 235-237. doi:  10.1111/j.1537-2995.2012.03934.x
    [15] Aqui NA, Stein SH, Konkle BA, et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura [J]. J ClinApher, 2003, 18: 51-54. doi:  10.1002/jca.10053
    [16] Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura [J]. Br J Haematol, 2005, 130: 768-776. doi:  10.1111/j.1365-2141.2005.05681.x
    [17] van Balen T, Schreuder MF, de Jong H, et al. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib [J]. Eur J Haematol, 2014, 92: 80-82. doi:  10.1111/ejh.12206
    [18] Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura [J]. Br J Haematol, 2007, 136: 146-149. doi:  10.1111/j.1365-2141.2006.06384.x
    [19] Ahmad HN, Thomas-Dewing RR, Hunt BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura [J]. Eur J Haematol, 2007, 78: 449-452. doi:  10.1111/j.1600-0609.2007.00832.x
    [20] Kremer Hovinga JA, Studt JD, DemarmelsBiasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura [J]. Haematologica, 2004, 89: 320-324.
    [21] Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients [J]. Blood, 2003, 102: 60-68. doi:  10.1182/blood-2003-01-0193
    [22] Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura [J]. Blood, 2015, 125: 1526-1531. doi:  10.1182/blood-2014-10-559211
    [23] Zheng X, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab [J]. Ann Intern Med, 2003, 138: 105-108. doi:  10.7326/0003-4819-138-2-200301210-00011
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (296) PDF downloads(387) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return